Role of HLA Antibodies in Graft Survival

HLA alloantibodies have been implicated in all three stages of allograft rejection – Hyperacute (including Accelerated), Acute and Chronic rejection. Hyperacute rejection occurs within minutes of transplant, Accelerated rejection occurs within days, Acute rejection occurs within days to weeks, while Chronic rejection occurs months to years post transplant. Antibody mediated rejection has a different pathology to T cell mediated rejection. Antibody mediated rejection preferentially attacks the peritubular and glomerular capillaries in contrast to T Cells which typically infiltrate the tubules and arterial endothelium.

 

Hyperacute rejection occurs almost immediately after the kidney is transplanted and is usually due to the presence of pre-formed donor specific anti-HLA antibodies. The mechanism of hyperacute rejection involves deposition of antibodies against HLA antigens expressed on the endothelium of the glomeruli and the graft microvasculature. This leads to activation of the classical complement cascade causing endothelial necrosis, platelet deposition and local coagulation. Hyperacute rejection is usually accompanied by C4d deposition, though this may be negative early on. Hyperacute rejection is not typically reversible and requires the immediate removal of the graft. Accelerated rejection usually occurs within days and is due to a memory or anamnestic response to pre-formed antibodies directed against mismatched donor antigen which are absent at the time of transplantation. Improved antibody screening and identification techniques as well as improvements in crossmatch techniques have significantly reduced the incidence of hyperacute and accelerated rejection.

 

Acute rejection occurs days to weeks (or months in the case of late acute rejection) post transplant and may contain a cellular as well as a humoral component. Acute humoral rejection is caused by pre-existing donor specific anti-HLA antibodies which are negative at the time of the pre-transplant crossmatch and/or de-novo donor specific antibodies. Diagnosis of Acute antibody mediated rejection involves identification of rapid graft dysfunction, accompanied by the presence of circulating anti-donor HLA antibodies and biopsy evidence of C4d deposition in the peritubular capillaries. C4d may also be deposited in the glomeruli though this is variable. Acute antibody mediated rejection is reversible with treatment such as plasmapheresis and intravenous immunoglobulin plus increased immunosuppression (with for example tacrolimus and mycophenolate mofetil). The Anti-CD20 antibody Rituximab is also used in some cases.

 

The role of alloantibodies in chronic rejection is increasingly being recognised. Recent data from the 14th international histocompatibility workshop demonstrated that four year deceased donor kidney allograft survival was 20% less in patients with donor specific antibodies compared to donors with no HLA antibodies. MICA antibodies were also demonstrated in these patients. Chronic rejection is characterised by slow progressive loss of renal function with endothelial antibody deposition leading to endothelial injury and glomerular basement membrane duplication characteristic of transplant glomerulopathy.

 

H&I laboratory tests carried out in support of the prevention or management of antibody mediated rejection in renal transplantation include HLA antibody screening and identification pre-transplant, crossmatching at the time of at the time of transplant as well as post transplant antibody monitoring either as part of a routine and regular program or at least at the time of suspected rejection episodes. These are important for the assessment of immunological risk prior to transplantation.

 

Current UK standards (BSHI/BTS 2010) require that HLA antibody screening and identification techniques used must be sufficient to identify antibodies to HLA-A, B, C, DR, DQ and DP. In addition, the testing must be able to distinguish IgG allo and IgM allo and auto antibodies. HLA antibody screening and identification has historically been by cell based techniques such as the complement dependent cytotoxicity (CDC) assay or by cell based flowcytometric assays. Currently however, most HLA antibody testing in the UK is by the solid phase Luminex bead based assays. These assays are much more sensitive than the traditional CDC techniques and require careful consideration of the clinical significance of Luminex positive, CDC negative tests.  Pre-transplant, this level of testing helps provide a list of unacceptable mismatches for renal patients, eliminating positive crossmatches and the impact this has in extending cold ischemia times.

 

Once a patient is listed for transplantation, HLA antibody testing must be undertaken every three months and 2 – 4 weeks after potentially sensitising events such as blood transfusion. This helps build up a full antibody profile for the patient, avoiding the risk of an unexpected positive crossmatch. HLA antibody investigation is to the same level of detail as described for pre listing. i.e. Antibodies to HLA-A, B, C, DR, DQ and DP must be identified and the testing must be able to distinguish IgG allo and IgM allo and auto antibodies. The unacceptable mismatches listed with the national organ sharing registry (NHSBT in the UK) must be updated.

 

In the live donor transplant setting initial crossmatches may be undertaken well in advance of the actual transplant as part of the donor selection process, with a final crossmatch at the time of transplantation. The purpose of any crossmatch test is to determine whether the patient has any preformed HLA antibodies which will react with antigens expressed by the donor and therefore helps to inform the immunological risk. In the UK, crossmatching is generally undertaken by CDC and/or flowcytometric assays. Cell separation techniques are used to ensure that reactivity to T and B cells can be distinguished. Tests used are also able to distinguish between IgG and IgM antibodies. In some centres, a virtual crossmatch is undertaken as the initial crossmatch in certain carefully selected cases.

 

At the time of transplant, antibody screening of the ‘current’ patient sample as well as pre-transplant crossmatching by CDC and flowcytometric techniques have significantly reduced the incidence of hyperacute rejection.

 

Post transplant, donor specific HLA antibodies contribute to acute humoral rejection characterised by rapid graft dysfunction, accompanied by the presence of circulating anti-donor HLA antibodies and biopsy evidence of C4d deposition in the peritubular capillaries. C4d may also be deposited in the glomeruli though this is variable. In addition, the role of HLA antibodies in chronic rejection is also increasingly recognised. Laboratory HLA antibody levels along with measures of graft function such as creatinine levels in kidney transplantation are used to help manage patients post transplant. The presence donor specific antibodies (DSA) post transplant does not necessarily indicate a need to treat. DSA in the absence of graft dysfunction (such as increasing creatinine levels for instance) needs close monitoring but does not always require treatment. Increasing levels of DSA in the presence of graft dysfunction such as increasing creatinine levels may indicate rejection. Treatment options include a change in immunosuppression and plasma exchange with or without IvIg. A reduction in DSA in the presence of graft dysfunction may also indicate possible rejection with antibodies being deposited on the graft. C4d deposition may also be a good surrogate for rejection in some cases, allowing for the fact that not all antibody mediated rejection involves Complement (e.g. antibody dependent cellular cytotoxicity – ADCC).

 

In HLA incompatible transplant, the role of H&I laboratory tests is crucial in monitoring the desensitisation to achieve a pre-transplant negative crossmatch as well as to closely monitor the patient post transplant for a rebound in antibody levels to help clinicians respond with therapies to reduce humoral rejection.

 

Ps. Get a copy of the eBook.

More Info...

  • You get all the content of this website in one easy to read pdf format
  • You get a list of over 300 references in H&I
  • You have access to all the articles even when offline
  • You can print at your leisure
  • You get pull out tables summarising disease associations
  • Finally you will be making a valuable contribution to the upkeep of this site.

Download a free copy of the eBook

Please follow me on Twitter @delordson

Leave a Reply